日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma

GM.CD40L疫苗联合CCL21治疗晚期肺腺癌患者的I期/随机II期临床

Jhanelle E Gray, Alberto Chiappori, Charlie C Williams, Tawee Tanvetyanon, Eric B Haura, Ben C Creelan, Jongphil Kim, Theresa A Boyle, Mary Pinder-Schenck, Farah Khalil, Soner Altiok, Rebecca Devane, David Noyes, Melanie Mediavilla-Varela, Renee Smilee, Emily L Hopewell, Linda Kelley, Scott J Antoni

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

CDK4/6 抑制可稳定 p16 基因缺失的非小细胞肺癌患者的病情,并与 mTOR 抑制产生协同作用

Priya K Gopalan, Andres Gordillo Villegas, Chunxia Cao, Mary Pinder-Schenck, Alberto Chiappori, Wei Hou, Maria Zajac-Kaye, Alison M Ivey, Frederic J Kaye

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

纳武利尤单抗(抗程序性死亡受体1抗体,BMS-936558,ONO-4538)治疗既往接受过治疗的晚期非小细胞肺癌患者的总生存期和长期安全性

Gettinger, Scott N; Horn, Leora; Gandhi, Leena; Spigel, David R; Antonia, Scott J; Rizvi, Naiyer A; Powderly, John D; Heist, Rebecca S; Carvajal, Richard D; Jackman, David M; Sequist, Lecia V; Smith, David C; Leming, Philip; Carbone, David P; Pinder-Schenck, Mary C; Topalian, Suzanne L; Hodi, F Stephen; Sosman, Jeffrey A; Sznol, Mario; McDermott, David F; Pardoll, Drew M; Sankar, Vindira; Ahlers, Christoph M; Salvati, Mark; Wigginton, Jon M; Hellmann, Matthew D; Kollia, Georgia D; Gupta, Ashok K; Brahmer, Julie R

Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study

一项随机、开放标签的II期研究,旨在评估Survivin反义寡核苷酸LY2181308联合多西他赛二线治疗非小细胞肺癌患者的抗肿瘤活性,并以肿瘤大小变化作为评价指标。

Natale, Ronald; Blackhall, Fiona; Kowalski, Dariusz; Ramlau, Rodryg; Bepler, Gerold; Grossi, Francesco; Lerchenmüller, Christian; Pinder-Schenck, Mary; Mezger, Jörg; Danson, Sarah; Gadgeel, Shirish M; Summers, Yvonne; Callies, Sophie; André, Valérie; Das, Mayukh; Lahn, Michael; Talbot, Denis

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors

HDAC 抑制剂帕比司他联合厄洛替尼治疗晚期呼吸消化道肿瘤患者的 I 期药代动力学和药效学研究

Jhanelle E Gray, Eric Haura, Alberto Chiappori, Tawee Tanvetyanon, Charles C Williams, Mary Pinder-Schenck, Julie A Kish, Jenny Kreahling, Richard Lush, Anthony Neuger, Leticia Tetteh, Angela Akar, Xiuhua Zhao, Michael J Schell, Gerold Bepler, Soner Altiok

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer

一项随机国际III期临床试验,比较基于ERCC1和RRM1表达的化疗方案与吉西他滨/卡铂方案治疗晚期非小细胞肺癌的疗效

Bepler, Gerold; Williams, Charles; Schell, Michael J; Chen, Wei; Zheng, Zhong; Simon, George; Gadgeel, Shirish; Zhao, Xiuhua; Schreiber, Fred; Brahmer, Julie; Chiappori, Alberto; Tanvetyanon, Tawee; Pinder-Schenck, Mary; Gray, Jhanelle; Haura, Eric; Antonia, Scott; Fischer, Juergen R